Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 4, 2010, Pages 1119-1123

  Li, Yan ^a,b   Huang, Xin En ^a,b   Yan, Peng Wei ^a,b   Jiang, Yong ^a,b   Xiang, Jin ^a  

^a JIANGSU CANCER HOSPITAL   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; Efficacy; Endostar; Safety; Solid tumors

Indexed keywords

EID: 78650685309     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Boehm T, Folkman J, Browder T, et al (1997). Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature, 390, 404-7.
2. Davis DW, Shen Y, Mullani NA, et al (2004). Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clin Cancer Res, 10, 33-42.
3. Eder JP Jr, Supko JG, Clark JW, et al (2002). Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol, 20, 3772-84.
4. Gehan EA, Tefft MC (2000). Will There Be Resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst, 92, 179-81.
5. Hansma AH, Broxterman HJ, van der Horst I, et al (2005). Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer. Ann Oncol, 16, 1695-701.
6. Herbst RS, Hess KR, Tran HT, et al (2002). Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol, 20, 3792-803.
7. Herbst RS, Lee AT, Tran HT, et al (2001). Clinical studies of angiogenesis inhibitors: The University of Texas MD Anderson Center Trial of human endostatin. Curr Oncol Rep, 3, 131-40.
8. Herbst RS, Mullani NA, Davis DW, et al (2002). Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol, 20, 3804-14.
9. Huang C, Li K (2008). Clinical analysis of advanced NSCLC treated by endostar in combination with NP. Zhonghua Zhong Liu Fang Zhi Za Zhi, 15, 283-5.
10. Jiang HQ, Li YL, Zou J (2007). Effect of recombinant human endostatin on endometriosis in mice. Chin Med J, 120, 1241-6.
11. Kulke MH, Bergsland EK, Ryan DP, et al (2006). Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol, 24, 3555-61.
12. Ling Y, Yang Y, Lu N, et al (2007). Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun, 361, 79-84.
13. Ling Y, Lu N, Gao Y, et al (2009). Endostar induces apoptotic effects in HUVECs through activation of caspase-3 and decrease of Bcl-2. Anticancer Res, 29, 411-8.
14. Lu N, Ling Y, Gao Y, et al (2008). Endostar suppresses invasion through downregulating the expression of matrix metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells. Exp Biol Med, 233,1013-20.
15. Ma CJ, Li YQ, Liu CY, et al (2008). The combination of tea polyphenols and rcombinant hman endostatin injection (Endostar) inhibits xenografted tumor growth of human lung adenocarcinoma A549. Zhongguo Zhong Yi Yao Xin Xi Za Zhi, 15, 41-3.
16. O'Reilly MS, Holmgren L, Chen C, et al (1996). Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med, 2, 689-92.
17. O'Reilly MS, Boehm T, Shing Y, et al(1997). Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell, 88, 277-85.
18. Shaheen RM, Davis DW, Liu W, et al (1999). Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor inhibits the growth of colon cancer liver metastases and induces tumor and endothelial cell apoptosis. Cancer Res, 59, 5412-6.
19. Shi HL, Xu LY, Liu Z (2004). Phase II clinical trial of homemade human rh-endostatin in the treatment of patients with stage IIIB-IVnon-small cell lung cancer. Zhongguo Fei Ai Za Zhi, 7, 325-8.
20. Song HF, Liu XW, Zhang HN, et al (2005). Pharmacokinetics of His-tag recombinant human endostatin in Rhesus monkeys. Acta Pharmacol Sin, 26, 124-8.
21. Sim BK, Fogler WE, Zhou XH, et al (1999). Zinc ligand-disrupted recombinant human Endostatin: Potent inhibition of tumor growth, safety and pharmacokinetic profile. Angiogenesis, 3, 41-51.
22. Thomas JP, Arzoomanian RZ, Albierti D, et al (2003). Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol, 21, 223-31.
23. Wang JW, Sun Y, Liu YY, et al (2005). Results of phase III trial of rh-endostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients. Zhongguo Fei Ai Za Zhi, 8, 283-90.
24. Wang J, Huang C, Wei XY, et al (2008). Changes of activated circulating endothelial cells and survivin in patients with non-small cell lung cancer after antiangiogenesis therapy. Chin Med J, 121, 2234-40.
25. Wu G, Zhang RG, Ren JH, et al (2008). Autophagic cell death of human hepatoma cells induced by Endostar, a recombinant human endostatin. Cancer Biother Radiopharm, 23, 735-40.
26. Xu FG, Ma QY, Sha HC (2007). Optimizing drug delivery for enhancing therapeutic efficacy of recombinant human endostatin in cancer treatment. Crit Rev Ther Drug Carrier Syst, 24, 445-92.
27. Yang L, Wang JW, Tang ZM, et al (2004). A phase I clinical trial for recombinant human endostatin. Zhongguo Xin Yao Za Zhi, 13, 548-53.
28. Yang L, Wang JW, Cui CX, et al (2005). Rh-endostatin (YH-16) in combination with vinorelbine and cisplatin for advanced non-small cell lung cancer: a multicenter phase II trial. Zhongguo Xin Yao Za Zhi, 14, 204-7.
29. Yang L, Wang JW, Sun Y, et al (2006). Randomized phase II trial on escalated doses of Rh-endostatin (YH-16) for advanced non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi, 28, 138-41.
30. Zhou ZW, Wan DS, Wang GQ, et al (2006). Inhibitory effect of angiogenesis inhibitor YH-16 on liver metastases from colorectal cancer. Chin J Cancer, 25, 818-22.